Explore Stanford technologies available for licensing:

Prematurity is the single largest cause of death in children under 5 years of age, both in low-and high-income countries.

Researchers in the Roncarolo have discovered transcription factors that enable the tracking and differentiation of type 1 T regulatory (Tr1) cells for the treatment of autoimmune conditions.

Researchers at Stanford have developed a potentially curative treatment strategy for alpha-thalassemia, one of the most common autosomal recessive disorders in the world involving the genes HBA1 and/or HBA2.

Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.

Stanford scientists developed Cardiac Conduction System (CCS) targeting monoclonal antibodies.

Stanford researchers have developed method for targeted application focused ultrasound to peripheral nerves to suppress acute pain.

Cancers including breast, lung, colon and prostate account for almost ten million deaths worldwide every year. The main cause of cancer deaths is metastasis, which is the propensity of cancer cells to spread throughout the body.

Stanford scientists have invented an implicit an Neural Representation learning methodology with Prior embedding (NeRP) to reconstruct a computational medical image from sparsely sampled measurements using only a prior image of the subject.

Stanford researchers developed a device that emits electromagnetic radiation that oscillates between at least first and second distinct polarization states.

The blood-brain barrier is a huge challenge when it comes to the delivery of therapeutic proteins to treat genetic diseases, injury, and neurodegenerative diseases.

Antimicrobial peptoids are promising leads for novel antibiotics; however, their activity is often compromised under physiological conditions. Inventors at Stanford enhanced the efficacy of antimicrobial peptoids by using thiourea and thiourea derivatives.

Stanford inventors have found that Stanniocalcin 2 (STC2) treatment following stoke leads to improved functional recovery and a pharmaceutical composition containing STC2 as an active ingredient can be used to facilitate post stroke recovery.

In 2021, almost 200,000 patients were diagnosed with leukemia and other blood and immune diseases in the US.

Stanford inventors in the Katrin Svensson laboratory have identified the protein Isthmin-1 (ISM1) as a treatment for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

Researchers at Stanford have identified a novel method of use for the drug T-5224 in the prevention of abdominal adhesion.